MELD-AFP-肿瘤负荷评分用于肝细胞癌肝切除术后预后分层
该研究基于多中心数据库850例接受根治性肝切除术的肝细胞癌患者,利用多因素Cox回归的加权β系数构建MELD-AFP-肿瘤负荷评分,将患者分为低危与高危两层,并在测试队列中验证其区分度优于巴塞罗那临床肝癌分期系统,同时提供了在线计算工具。
要点
- MELD、对数转换AFP与肿瘤负荷评分均为总生存的独立预测因素。
- 该评分将训练队列分为低危5年OS 70.5%与高危5年OS 47.0%(P < .001)。
- 测试队列C指数0.72,优于BCLC分期的0.53,可用于识别高危患者。
核心结论
- MELD-AFP-肿瘤负荷评分是肝细胞癌肝切除术后预后分层的准确新工具,可识别可能从替代治疗中获益的高危患者。
研究设计与样本
- 研究使用多机构数据库,纳入接受根治性肝切除术的肝细胞癌患者共850例,其中训练队列595例(70.0%)、测试队列255例(30.0%);采用多因素Cox回归的加权β系数构建总生存预测评分。
主要发现
- 训练队列多因素分析显示MELD(HR 1.04;95%CI 1.01-1.07)、对数转换AFP(HR 1.07;95%CI 1.02-1.13)和肿瘤负荷评分(HR 1.07;95%CI 1.03-1.11)为总生存更差的独立预测因素。
- 训练队列中低危组466例(78.3%)5年OS为70.5%,高危组129例(21.7%)5年OS为47.0%(P < .001)。
- 测试队列中该评分C指数为0.72,1年、3年、5年时间依赖AUC分别为0.80、0.76、0.70,优于BCLC分期的C指数0.53及对应AUC 0.61、0.55、0.56。
关键数值与推荐
- 评分基于MELD、对数转换AFP与肿瘤负荷评分三项指标的Cox模型加权β系数构建。
- 训练队列分层界值对应低危组5年OS 70.5%、高危组5年OS 47.0%。
- 在线计算工具发布于https://jk-osu.shinyapps.io/MELD_AFP_TBS/。
临床怎么用
- 对拟行根治性肝切除术的肝细胞癌患者,可用该评分进行术前预后分层,高危患者应考虑替代或联合治疗策略并加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Morphologic criteria, such as the Barcelona Clinic Liver Cancer staging system often fail to accurately predict long-term survival among patients undergoing liver resection for hepatocellular carcinoma. We sought to develop a continuous risk score that incorporates established markers of tumor biology and liver function to improve the prediction of overall survival. METHODS: Data from a multi-institutional database were used to identify patients who underwent curative-intent hepatectomy for hepatocellular carcinoma. A predictive score for overall survival was developed using weighted beta-coefficients from a multivariable Cox regression model. RESULTS: Among 850 patients, 595 (70.0%) were assigned to the training cohort, and 255 (30.0%) to the test cohort. In the training cohort, multivariable analysis identified the Model of End-Stage Liver Disease (hazard ratio, 1.04; 95% confidence interval, 1.01-1.07), log-transformed alpha-fetoprotein (hazard ratio, 1.07; 95% confidence interval, 1.02-1.13), and tumor burden score (hazard ratio, 1.07; 95% confidence interval, 1.03-1.11) as independent predictors of worse overall survival. The Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden score, based on the Cox model, stratified patients into low-risk (n = 466, 78.3%) with a 5-year OS of 70.5% and high-risk (n = 129, 21.7%) with a 5-year OS of 47.0% (P < .001). In the test cohort, the Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden score demonstrated superior discriminative accuracy (C-index: 0.72, time-dependent area under the curve 1-year: 0.80, 3-year 0.76, 5-year 0.70) compared with the Barcelona Clinic Liver Cancer staging system (C-index: 0.53, time-dependent area under the curve 1-year: 0.61, 3-year 0.55, 5-year 0.56). An online tool was made accessible at https://jk-osu.shinyapps.io/MELD_AFP_TBS/. CONCLUSION: The Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden score provides a novel, accurate tool for prognostic stratification of patients with hepatocellular carcinoma, identifying high-risk patients who may benefit from alternative treatments to improve outcomes.
引用
- Kawashima J, Akabane M, Khalil M, et al. Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden (MELD-AFP-TBS) score to stratify prognosis after liver resection for hepatocellular carcinoma. Surgery. 2025. PMID: 40311416. doi:10.1016/j.surg.2025.109388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。